Background: The genes encoding type I interferons (IFNs), which include 14 IFN-α genes, 1 IFN-β gene, 1 IFN-ω (also known as IFN-α II1) gene, and a number of IFN-ω pseudogenes, are clustered on human chromosome 9. Interferons-α and -β are cytokines that are widely known to induce potent anti-viral activity. IFN-α and -β exert a variety of other biological effects, including anti-tumor and immunomodulatory activities and are increasingly used clinically to treat a range of malignancies, myelodysplasias and autoimmune diseases. IFN-ω is antigenically different from human IFN-α, IFN-β, IFN-τ or IFN-γ, but is a component of natural mixtures of IFN species produced by virus-induced leukocytes or Burkitt's lymphoma cells. IFN-τ, a secreted monomer used in treatment for multiple sclerosis, has antiviral, antibacterial and anticancer activities. The Type I interferon receptor (IFN-αR) interacts with IFN-α, IFN-β and IFN-ω, and seems to be a multisubunit receptor.
Description: Rabbit polyclonal to IFNE1
Immunogen: KLH conjugated synthetic peptide derived from IFNE1
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 22 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
